Seattle biotech startup Good Therapeutics raised another $11 million to create “context dependent” protein drugs that act only when needed. The 4-year-old company is developing cytokines that regulate their own activity in response to biomarkers and metabolic signals, said CEO John Mulligan. It is focused initially on immuno-oncology applications. The $11 million follows another $11 million cash infusion raised last year to complete a $22 million Series A financing round. Investors include Roche Venture Fund; Rivervest Venture Partners; 3X5 Partners; Digitalis Ventures; and Codon Capital.